JPWO2021033729A1 - - Google Patents

Info

Publication number
JPWO2021033729A1
JPWO2021033729A1 JP2021540972A JP2021540972A JPWO2021033729A1 JP WO2021033729 A1 JPWO2021033729 A1 JP WO2021033729A1 JP 2021540972 A JP2021540972 A JP 2021540972A JP 2021540972 A JP2021540972 A JP 2021540972A JP WO2021033729 A1 JPWO2021033729 A1 JP WO2021033729A1
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021540972A
Other versions
JP7409383B2 (ja
JPWO2021033729A5 (ja
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of JPWO2021033729A1 publication Critical patent/JPWO2021033729A1/ja
Publication of JPWO2021033729A5 publication Critical patent/JPWO2021033729A5/ja
Application granted granted Critical
Publication of JP7409383B2 publication Critical patent/JP7409383B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D205/00Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02Dicarboxylic acids
    • C07C55/10Succinic acid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/01Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
    • C07C65/03Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2021540972A 2019-08-20 2020-08-19 S1p5受容体作動活性を有する化合物の塩および結晶形 Active JP7409383B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962889091P 2019-08-20 2019-08-20
US62/889,091 2019-08-20
PCT/JP2020/031326 WO2021033729A1 (ja) 2019-08-20 2020-08-19 S1p5受容体作動活性を有する化合物の塩および結晶形

Publications (3)

Publication Number Publication Date
JPWO2021033729A1 true JPWO2021033729A1 (ja) 2021-02-25
JPWO2021033729A5 JPWO2021033729A5 (ja) 2022-09-14
JP7409383B2 JP7409383B2 (ja) 2024-01-09

Family

ID=74660224

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021540972A Active JP7409383B2 (ja) 2019-08-20 2020-08-19 S1p5受容体作動活性を有する化合物の塩および結晶形

Country Status (13)

Country Link
US (1) US20220289675A1 (ja)
EP (1) EP4019496B1 (ja)
JP (1) JP7409383B2 (ja)
KR (1) KR20220050886A (ja)
CN (1) CN114302873A (ja)
AU (1) AU2020334489A1 (ja)
BR (1) BR112022002632A2 (ja)
CA (1) CA3150303A1 (ja)
IL (1) IL290432A (ja)
MX (1) MX2022001820A (ja)
TW (1) TW202114984A (ja)
WO (1) WO2021033729A1 (ja)
ZA (1) ZA202201784B (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024522718A (ja) * 2021-06-16 2024-06-21 セルジーン コーポレーション 神経変性疾患の治療のための、カルボン酸基を含むアゼチジニル化合物
WO2024129948A1 (en) * 2022-12-16 2024-06-20 Celgene Corporation Heterocyclic compounds as modulators of s1p5

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01149790A (ja) * 1987-10-27 1989-06-12 Ciba Geigy Ag 新規なリファマイシン誘導体
JPH02500744A (ja) * 1986-11-21 1990-03-15 アクチエボラゲツト・ヘツスレ 新規な薬学的化合物
WO2006064757A1 (ja) * 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
JP2009540006A (ja) * 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト N−ヒドロキシ−3−[4−[[[2−(2−メチル−1h−インドール−3−イル)エチル]アミノ]メチル]フェニル]−2e−2−プロペンアミドの多形
WO2016088834A1 (ja) * 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
JP7211410B2 (ja) * 2018-02-22 2023-01-24 小野薬品工業株式会社 S1p5受容体作動活性を有する化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005020882A (ja) 2003-06-25 2005-01-20 Matsushita Electric Works Ltd モータアクチュエータ装置
JP2006064757A (ja) 2004-08-24 2006-03-09 Systec Kyowa:Kk ディスプレイ固定用スタンド

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02500744A (ja) * 1986-11-21 1990-03-15 アクチエボラゲツト・ヘツスレ 新規な薬学的化合物
JPH01149790A (ja) * 1987-10-27 1989-06-12 Ciba Geigy Ag 新規なリファマイシン誘導体
WO2006064757A1 (ja) * 2004-12-13 2006-06-22 Ono Pharmaceutical Co., Ltd. アミノカルボン酸誘導体およびその医薬用途
JP2009540006A (ja) * 2006-06-12 2009-11-19 ノバルティス アクチエンゲゼルシャフト N−ヒドロキシ−3−[4−[[[2−(2−メチル−1h−インドール−3−イル)エチル]アミノ]メチル]フェニル]−2e−2−プロペンアミドの多形
WO2016088834A1 (ja) * 2014-12-04 2016-06-09 小野薬品工業株式会社 ジヒドロナフタレン誘導体
JP7211410B2 (ja) * 2018-02-22 2023-01-24 小野薬品工業株式会社 S1p5受容体作動活性を有する化合物
JP2023029542A (ja) * 2018-02-22 2023-03-03 小野薬品工業株式会社 S1p5受容体作動活性を有する化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
"Pharmaceutical Salts", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 66, no. 1, JPN6014023656, 1977, pages 1 - 19, ISSN: 0005114159 *
小嶌隆史: "医薬品開発における結晶性選択の効率化を目指して", 薬剤学, vol. 68, no. 5, JPN6009053757, 1 September 2008 (2008-09-01), pages 344 - 349, ISSN: 0005114156 *
芦澤 一英: "塩・結晶形の最適化と結晶化技術", PHARM TECH JAPAN, vol. 18, no. 10, JPN6013060608, 2002, pages 81 - 96, ISSN: 0005114157 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005114158 *

Also Published As

Publication number Publication date
BR112022002632A2 (pt) 2022-05-03
EP4019496A1 (en) 2022-06-29
AU2020334489A1 (en) 2022-03-03
JP7409383B2 (ja) 2024-01-09
EP4019496B1 (en) 2024-06-05
ZA202201784B (en) 2024-02-28
MX2022001820A (es) 2022-03-17
IL290432A (en) 2022-04-01
US20220289675A1 (en) 2022-09-15
WO2021033729A1 (ja) 2021-02-25
CN114302873A (zh) 2022-04-08
KR20220050886A (ko) 2022-04-25
CA3150303A1 (en) 2021-02-25
TW202114984A (zh) 2021-04-16
EP4019496A4 (en) 2023-01-11

Similar Documents

Publication Publication Date Title
BR112021017339A2 (ja)
BR112021018450A2 (ja)
BR112021017939A2 (ja)
BR112021017892A2 (ja)
AU2020104490A4 (ja)
BR112021017738A2 (ja)
BR112021017782A2 (ja)
BR112021018168A2 (ja)
BR112021017728A2 (ja)
BR112021018452A2 (ja)
BR112021017234A2 (ja)
BR112021017355A2 (ja)
BR112021017703A2 (ja)
BR112021017173A2 (ja)
BR112021018102A2 (ja)
BR112021017083A2 (ja)
BR112021017637A2 (ja)
JPWO2021033729A1 (ja)
BR112021018250A2 (ja)
BR112021018084A2 (ja)
BR112021018093A2 (ja)
BR112021018484A2 (ja)
BR112021017732A2 (ja)
BR112021017949A2 (ja)
BR112021017983A2 (ja)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220906

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220906

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231025

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231108

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231204

R150 Certificate of patent or registration of utility model

Ref document number: 7409383

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150